MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
128.67
+0.77
+0.60%
After Hours: 128.01 -0.66 -0.51% 18:40 03/01 EST
OPEN
127.18
PREV CLOSE
127.90
HIGH
130.59
LOW
124.90
VOLUME
1.68M
TURNOVER
0
52 WEEK HIGH
159.89
52 WEEK LOW
55.25
MARKET CAP
12.08B
P/E (TTM)
-22.1818
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SRPT last week (0226-0301)?
Weekly Report · 1h ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sarepta Therapeutics, Inc. Shares fell 5.8% to US$129 in the week after its latest yearly results. The company reported revenues of US$1.2b, but statutory losses were 9.2% smaller than expected. The analysts have downgraded their revenue and earnings per share estimates for the company. SareptaTherapeutics is expected to grow faster than its industry in the years to come. We have gathered the latest post-earnings forecasts for the business.
Simply Wall St · 1d ago
Sarepta Therapeutics Inc: Report of proposed sale of securities
Press release · 2d ago
UBS Maintains Buy on Sarepta Therapeutics, Raises Price Target to $167
Benzinga · 2d ago
Sarepta Therapeutics (SRPT) Gets a Hold from Oppenheimer
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Advancements
TipRanks · 3d ago
Buy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising Outlook
TipRanks · 3d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.